French oncology specialist Nanobiotix has strengthened its US leadership team with the appointments of Dr Mihail Obrocea and Noël Kurdi.
Dr Obrocea (pictured right) joins Nanobiotix as head of US clinical development, bringing 20 years of clinical research leadership to the role.
Most recently, Dr Obrocea was AbbVie Biotherapeutics’ project director and oncology clinical lead, overseeing a number of trials in oncology and hematology.
He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.
Meanwhile, Kurdi (pictured left) becomes director of investor relations at Nanobiotix, moving from the Trout Group where she served as a senior associate.
Kurdi has previously worked in institutional equity sales and research at Brean Capital, and business development and investor relations at AIG Investments in New York.